SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-012545
Filing Date
2023-03-20
Accepted
2023-03-20 16:15:28
Documents
14
Period of Report
2023-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10050022_8k.htm   iXBRL 8-K 25954
2 EXHIBIT 99.1 brhc10050022_ex99-1.htm EX-99.1 136499
6 image0.jpg GRAPHIC 37360
  Complete submission text file 0001140361-23-012545.txt   361502

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20230320.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20230320_lab.xml EX-101.LAB 22546
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20230320_pre.xml EX-101.PRE 16044
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10050022_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 23746563
SIC: 2834 Pharmaceutical Preparations